Dr. Rodrigo C. Leão Edelmuth

Dr. Rodrigo C. Leão Edelmuth


Dr. Rodrigo C. Leão Edelmuth is a board certified digestive surgeon at Hospital Israelita Albert Einstein in São Paulo, Brazil. He holds his General Surgery and Digestive Surgery degree from São Paulo University Medical School. He underwent a postgraduate course on Surgical Leadership at Harvard Medical School and a Research Fellowship in the Department of Surgery at Weill Cornell Medicine in New York. Dr. Edelmuth is member of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) and of the Society for Surgery of the Alimentary Tract (SSAT). In 2022 he received the SAGES Career Development Award.
Menin Inhibitors: Interpreting Impact On Acute Myeloid Leukemia (AML) Treatment Play
Menin Inhibitors: Interpreting Impact On Acute Myeloid Leukemia (AML) Treatment
By Dr. Rodrigo C. Leão Edelmuth
Jaypirca: A Promising Therapy Against Chronic Lymphocytic Leukemia Play
Jaypirca: A Promising Therapy Against Chronic Lymphocytic Leukemia
By Dr. Rodrigo C. Leão Edelmuth
SurvivorNet In Honolulu: The Biggest Glioma Headlines From SNO 2025 & What They Mean For Patients Play
SurvivorNet In Honolulu: The Biggest Glioma Headlines From SNO 2025 & What They Mean For Patients
By Dr. Rodrigo C. Leão Edelmuth
Balancing Realism With Optimism In Glioma Treatment Play
Balancing Realism With Optimism In Glioma Treatment
By Dr. Rodrigo C. Leão Edelmuth
More IDH Inhibitor Success, Better Quality Of Life & The Potential For Expanded Use: The Biggest News From 2025’s SNO Meeting Play
More IDH Inhibitor Success, Better Quality Of Life & The Potential For Expanded Use: The Biggest News From 2025’s SNO Meeting
By Dr. Rodrigo C. Leão Edelmuth
A New Drug Offers ‘Exciting’ Option For Diffuse Midline Glioma Patients Play
A New Drug Offers ‘Exciting’ Option For Diffuse Midline Glioma Patients
By Dr. Rodrigo C. Leão Edelmuth
A Potential Game-Changer in Prostate Cancer: A Simple Genomic Test Can Tell Us Who Needs Hormone Therapy And Who Doesn’t
A Potential Game-Changer in Prostate Cancer: A Simple Genomic Test Can Tell Us Who Needs Hormone Therapy And Who Doesn’t
By Dr. Rodrigo C. Leão Edelmuth
Low Grade Glioma – Vorasidenib and the Changing Care of IDH-Mutant Grade 2 Glioma
Low Grade Glioma – Vorasidenib and the Changing Care of IDH-Mutant Grade 2 Glioma
By Dr. Rodrigo C. Leão Edelmuth
Durvalumab + FLOT Keeps Gastric Cancer Under Control Longer, MATTERHORN Trial Shows
Durvalumab + FLOT Keeps Gastric Cancer Under Control Longer, MATTERHORN Trial Shows
By Dr. Rodrigo C. Leão Edelmuth
The DESTINY Trial Confirms Top Second-Line Approach For HER2+ Advanced Gastric Cancer
The DESTINY Trial Confirms Top Second-Line Approach For HER2+ Advanced Gastric Cancer
By Dr. Rodrigo C. Leão Edelmuth
A Better Option For Some Women With Advanced HR+, HER2- Breast Cancer: Examining Data From The SERENA-6 Trial
A Better Option For Some Women With Advanced HR+, HER2- Breast Cancer: Examining Data From The SERENA-6 Trial
By Dr. Rodrigo C. Leão Edelmuth
Avutometinib Plus Defactinib Gets Accelerated Approval for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Avutometinib Plus Defactinib Gets Accelerated Approval for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
By Dr. Rodrigo C. Leão Edelmuth
Insights from the AURIGA Trial: Daratumumab-Based Maintenance Therapy in Newly Diagnosed Multiple Myeloma Play
Insights from the AURIGA Trial: Daratumumab-Based Maintenance Therapy in Newly Diagnosed Multiple Myeloma
By Dr. Rodrigo C. Leão Edelmuth
FDA Approval For Imlunestrant: Principal Investigator Dr. Jhaveri On The Practice Changing Impact For Advanced ER+/HER2- Breast Cancer Patients Play
FDA Approval For Imlunestrant: Principal Investigator Dr. Jhaveri On The Practice Changing Impact For Advanced ER+/HER2- Breast Cancer Patients
By Dr. Rodrigo C. Leão Edelmuth
ESMO News: Advancements in First-Line Treatment for Metastatic Castration-Resistant Prostate Cancer
ESMO News: Advancements in First-Line Treatment for Metastatic Castration-Resistant Prostate Cancer
By Dr. Rodrigo C. Leão Edelmuth
Systemic Therapy for Advanced Gastric Cancer: Current Approaches and Emerging Strategies Play
Systemic Therapy for Advanced Gastric Cancer: Current Approaches and Emerging Strategies
By Dr. Rodrigo C. Leão Edelmuth
The Evolution of Metastatic Breast Cancer Treatment: Exploring the Options
The Evolution of Metastatic Breast Cancer Treatment: Exploring the Options
By Dr. Rodrigo C. Leão Edelmuth
Endocrine Therapies vs. ADCs: Should Antibody Drug Conjugates Be Moved Earlier in the Treatment Process? Play
Endocrine Therapies vs. ADCs: Should Antibody Drug Conjugates Be Moved Earlier in the Treatment Process?
By Dr. Rodrigo C. Leão Edelmuth
Enhertu Approval: New Opportunities for Antibody-Drug Conjugates in Lung Cancer Therapy
Enhertu Approval: New Opportunities for Antibody-Drug Conjugates in Lung Cancer Therapy
By Dr. Rodrigo C. Leão Edelmuth
Understanding Pluvicto (Lutetium-177) and PSMA PET Scans in Prostate Cancer Treatment Play
Understanding Pluvicto (Lutetium-177) and PSMA PET Scans in Prostate Cancer Treatment
By Dr. Rodrigo C. Leão Edelmuth
Treating Prostate Cancer: The Value of a Team Approach Play
Treating Prostate Cancer: The Value of a Team Approach
By Dr. Rodrigo C. Leão Edelmuth
Integrating Genetic Testing and PARP Inhibitors in Prostate Cancer Management
Integrating Genetic Testing and PARP Inhibitors in Prostate Cancer Management
By Dr. Rodrigo C. Leão Edelmuth
Natural Killer Cells: Is This The Next Generation of Immunotherapy? Understanding The FDA Approval in Bladder Cancer Play
Natural Killer Cells: Is This The Next Generation of Immunotherapy? Understanding The FDA Approval in Bladder Cancer
By Dr. Rodrigo C. Leão Edelmuth
The Latest in Managing Anemia for Patients With Myelodysplastic Syndrome (MDS)
The Latest in Managing Anemia for Patients With Myelodysplastic Syndrome (MDS)
By Dr. Rodrigo C. Leão Edelmuth
Rytelo Gains FDA Approval for Lower-Risk Myelodysplastic Syndrome: Reducing Need For Blood Transfusions & Improving Quality of Life
Rytelo Gains FDA Approval for Lower-Risk Myelodysplastic Syndrome: Reducing Need For Blood Transfusions & Improving Quality of Life
By Dr. Rodrigo C. Leão Edelmuth
Studies Indicate Lynparza Extends Life of Patients with Advanced Stage Ovarian Cancer
Studies Indicate Lynparza Extends Life of Patients with Advanced Stage Ovarian Cancer
By Dr. Rodrigo C. Leão Edelmuth

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider
close-icon

MHQ: Clinical IntelligencePowered by SurvivorNet

  • health-panel

    Health Panel

  • clinical-trial

    Clinical Trials

    ?
Prefer to talk instead of typing?
close-icon

Answers offered are informational and do not constitute medical advice. Learn more

close-icon
Health Profile

Enter health info to personalize results.

What is your gender?

What is your age?

close-icon
Clinical Trials

clinical-icon

filter

Clear List

Ask me anything about your health...

I’m listening

thinking

responding

close-icon close-icon
close-icon
close-icon
close-icon